Best Pcsk9 Podcasts (2024)

1
ASCVD Series - Part 3-The Next Top Model: Activating & Improving Systems of Care 25:46

1+ y ago25:46

25:46

Listen as Dr. Howard Haft & Dr. Tracy Yu-Ping Wang discuss techniques on how to improve the transition of care for ASCVD patients into the outpatient setting – and how social determinants of health play a factor in treatment plans.

1
ASCVD Series - Part 2-Looking Ahead in ASCVD 16:18

1+ y ago16:18

16:18

One of the biggest challenges for newly diagnosed ASCVD patients is medication adherence. Listen as Dr. Michelle Chu, PharmD discusses how to work with patients who are struggling to adapt to their new lifestyle and the importance of integrating their care givers into the conversation.

1
ASCVD Series - Part 1-The Importance of Bridging the Gap in Lipid Management 19:29

1+ y ago19:29

19:29

How does the equity gap play a role in lipid management? Join us as we interview Dr. Keith Ferdinand on the importance of recognizing & addressing implicit bias in cardiovascular care, and what he is doing at Tulane University to train future physicians in this subject matter.

1
Statin and Non-Statin Drugs 37:40

3y ago37:40

37:40

Statins are the cornerstone of lipid lowering drugs. Listen as Drs. Natarajan, Michos, and Kara discuss the role of statins for cardiovascular disease prevention as well as new incorporation of some non-statin cholesterol-lowering medications in 2018 AHA/ACC Cholesterol Guidelines.By American Heart Association

1
Coronary Calcification (CAC Score) 47:14

3y ago47:14

47:14

A deep dive discussion between Drs. Pradeep Natarajan, Ron Blankstein and Khurram Nasir in assessment of Coronary artery calcium (CAC) to help guide prognosis and management. In this podcast learn the role of CAC score.By American Heart Association

1
Uses of PCSK9 Inhibitors 20:35

3y ago20:35

20:35

Listen as Drs. Ferguson and Musunuru review history and uses of PCSK9 inhibitors and how these drugs can transform cardiovascular medicine.By American Heart Association

1
New Discoveries in Cholesterol Metabolism 25:06

3y ago25:06

25:06

Despite medications to reduce risk of heart cardiovascular disease; heart disease is still the number one leading cause of death in the United States as well as around the world. Listen to Drs. Ferguson and Musunuru as they review new discoveries in cholesterol metabolism and explore why researchers are continuing to study cholesterol metabolism ve…

1
ASCVD Risk Calculator 28:52

3y ago28:52

28:52

Atherosclerotic Cardiovascular Disease (ASCVD). risk calculator is a tool that enables healthcare providers and patients to estimate ten-year and lifetime risk of ASCVD. Listen as Dr. Virani explores the reasons why should healthcare professionals should perform ASCVD risk assessment and how the ASCVD Risk Calculator can be used.…

1
Familial Hypercholesterolemia 22:57

3y ago22:57

22:57

What is the prevalence of familial hypercholesterolemia? Learn more as Drs. Mehta and Orringer examine the 2018 cholesterol guidelines and how familial hypercholesterolemia and its treatment fall into the new guideline.By American Heart Association

1
Women’s CVD and the Cholesterol Guidelines 22:15

3y ago22:15

22:15

Cardiovascular disease is the leading cause of death for women in the US and worldwide. Listen as Drs. Mehta, Braun, and Lundberg discuss the importance of adding women-specific factors in the guideline and focus on many important areas common in women’s health that includes rheumatologic disorders, such as rheumatoid arthritis, systemic lupus eryt…

1
New Guideline Changes 18:15

3y ago18:15

18:15

The 2018 AHA/ACC cholesterol guideline address the management of patients with high blood cholesterol and other disorders, and risks for atherosclerotic cardiovascular disease. Listen as Dr. Pradeep Natarajan discusses the important changes in 2018 AHA/ACC Cholesterol Guidelines and comparing them to the 2013 cholesterol guideline.…

1
Laure Frésard, Nicole Ferraro, & Nikki Teran: IDing Rare Disease Genes 9:09

5y ago9:09

9:09

Nikki Teran, Laure Frésard, and Nicole Ferraro talk about their work diagnosing rare diseases. We pick apart their abstract to see how they, along with other clinicians and scientists, look at differences between the RNA from patient's and healthy people's blood in order to find out which genes are broken. See the full article at: https://www.natur…

1
Dirk Spencer: Plant Communication 9:30

5+ y ago9:30

9:30

We talk with Dirk Spencer about his recent work at Simon Gilroy’s lab at UW Madison where he helped lead author, Masatusugu Toyota, observe plants reacting to being eaten by caterpillars. Join us as we pick apart their abstract to see how they used fluorescent markers to begin to dissect plant “intelligence”.…

1
Tess Branon: Directing Evolution to Craft New Biotechnology 9:10

5+ y ago9:10

9:10

We talk with Tess Branon about TurboID, a new tool she developed in Alice Ting's lab at MIT and Stanford University. TurboID can be added to any protein to label what’s around it, letting scientists find out what a protein’s doing by who it’s interacting with — even in whole animals. We pick apart Tess's abstract to see how she used directed evolut…

1
Abhiram Rao: PCSK9 & Drug Safety Prediction 4:56

5+ y ago4:56

4:56

We look at Stanford grad student, Abhiram Rao's study on a gene named PCSK9, which makes a protein involved in cholesterol regulation. We pick apart his abstract to see how he used genomics to show that PCSK9 inhibitor drugs could protect against stroke. See the original article at: www.ahajournals.org/doi/10.1161/CIRCGEN.118.002162…

1
Treating Erectile Dysfunction: Key Cardiovascular Considerations

7+ y ago

—

Host: Alan S. Brown, MD, FACC, FAHA, FNLA Live from the Clinical Lipid Update of the National Lipid Association in Amelia Island, FL, host Dr. Alan Brown welcomes Dr. Robert Kloner, Vice President of Translation at Huntington Medical Research Institutes and Professor of Medicine in the Cardiovascular Division of Keck School of Medicine at the Unive…

1
Pharmacometabolomics to Predict Statin Response: Ready for Prime Time?

7+ y ago

—

Host: Alan S. Brown, MD, FACC, FAHA, FNLA Live from the Clinical Lipid Update of the National Lipid Association in Amelia Island, FL, host Dr. Alan Brown welcomes Dr. Rhoda Cooper-DeHoff. Dr. Cooper-DeHoff is an Associate Professor in the Department of Pharmacotherapy and Translational Research and Division of Cardiovascular Medicine of the College…

1
Triglyceride-Lowering Therapies: Addressing Gaps in the Guidelines

7+ y ago

—

Host: Alan S. Brown, MD, FACC, FAHA, FNLA Live from the Clinical Lipid Update of the National Lipid Association in Amelia Island, FL, host Dr. Alan Brown welcomes Dave Dixon, PharmD, Clinical Pharmacist and Associate Professor of Pharmacology at Virginia Commonwealth University School of Pharmacy. Dr. Dixon is also a Board Certified Pharmacotherapy…

1
PCSK9 Antibodies for Dyslipidemia: Efficacy, Safety, and Non-Lipid Effects

7+ y ago

—

Host: Alan S. Brown, MD, FACC, FAHA, FNLA Live from the Clinical Lipid Update of the National Lipid Association in Amelia Island, FL, host Dr. Alan Brown welcomes Dr. Eugenia Gianos. Dr. Gianos is an assistant professor in the Department of Medicine and co-clinical director of the Center for the Prevention of Cardiovascular Disease at the NYU Schoo…

1
Canadian Perspectives on Managing Lipid Disorders in Children

8y ago

—

Host: Alan S. Brown, MD, FACC, FAHA, FNLA Like in the United States, Canadian citizens contend with a high pediatric prevelance of lipid disorders, particularly familial hypercholesterolemia. However, perspectives on clinical care and standards public health priorities to address dyslipidemia differ markedly between these two countries. Can America…

1
Pathogenesis and Management of Non-Alcoholic Fatty Liver Disease

8y ago

—

Host: Alan S. Brown, MD, FACC, FAHA, FNLA Patients in lipidolgy clinics sometimes undergo diagnostic workups for mild liver enzyme elevations, and in select cases a diagnosis of non-alcoholic fatty liver disease will be made. How does this diagnosis compare with the more inflammatory alcoholic fatty liver disease, and what roles should the lipidolo…

1
Lipid-Lowering Drug Interactions in Cardiovascular Agents

8y ago

—

Host: Alan S. Brown, MD, FACC, FAHA, FNLA Joining Dr. Alan Brown to discuss the pharmacokinetic data behind drug interactions between treatments for complex lipid abnormalities is Dr. Barbara Wiggins, Pharm.D, clinical pharmacy specialist in cardiology at the Medical University of South Carolina and adjunct professor at the South Carolina School of…

1
Selecting the Right Contraception for the Dyslipidemic Woman

8y ago

—

Host: Alan S. Brown, MD, FACC, FAHA, FNLA Guest: Robert Wild, MD, MPH, D.Phil. Recorded live at the recent Annual National Lipid Association meeting, Dr. Alan Brown welcomes Dr. Robert Wild to discuss types of dyslipidemia that clinicans may see in women of child bearing age, particularly those using hormonal contraception. The two discuss ways for…

1
Lipidologists Confronting the Obesity Epidemic: Perspectives from NLA President Joyce Ross

8y ago

—

Host: Alan S. Brown, MD, FACC, FAHA, FNLA Guest: Joyce Ross Host Dr. Alan Brown welcomes Joyce Ross, nurse practitioner and President of the National Lipid Association. Joyce is a consultative education specialist in Cardiovascular Risk Intervention with the University of Pennsylvania Health System. She is the first Nurse Practitioner elected as Pr…

1
Big Data in Lipids: Refining Cardiovascular Risk Profiles Nationwide

8y ago

—

Host: Alan S. Brown, MD, FACC, FAHA, FNLA Host Dr. Alan Brown welcomes Dr. Seth Martin, cardiologist and assistant professor of medicine at the Johns Hopkins University School of Medicine with a joint appointment in epidemiology at the Johns Hopkins Bloomberg School of Public Health. Dr. Martin is a faculty member in the Johns Hopkins Ciccarone Cen…

1
Cardiovascular Risk Reduction in the Elderly: Best Lipid Strategies

8y ago

—

Host: Alan S. Brown, MD, FACC, FAHA, FNLA Guest: Joyce Ross, MSN, CRNP, CS, CLS, FNLA, FPCNA Host Dr. Alan Brown welcomes Joyce Ross, MSN, CRNP, FNLA, President-Elect of the National Lipid Association. Joyce serves as a consultative education specialist in cardiovascular risk intervention with the University of Pennsylvania Health System. Their dis…

1
What's the Deal with Saturated Fat and Cardiovascular Disease Risk?

8y ago

—

Host: Alan S. Brown, MD, FACC, FAHA, FNLA Dr. Alan Brown welcomes Dr. Penny Kris-Etherton, Distinguished Professor of Nutrition at Penn State and Past President of NLA. Dr. Kris-Etherton reviews the current dietary recommendations for saturated fat for the population at large and for reducing LDL-C levels. The two discuss the evidence to support th…

1
Lipidology's Advances and Growing Pains: Technologies, Drug Trials, and Guidelines

8y ago

—

Host: Alan S. Brown, MD, FACC, FAHA, FNLA Host Dr. Alan Brown welcomes Dr. Steven Nissen, Chairman of the Department of Cardiovascular Medicine and Professor of Medicine at the Lerner School of Medicine of the Cleveland Clinic. The two focus on some of the major developments in lipidology today, from roles of intravascular ultrasound to updates in …

1
The Lipidology Essentials: Making of a Specialty's Annual Summary

8y ago

—

Host: Alan S. Brown, MD, FACC, FAHA, FNLA Guest: Harold Bays, MD, FNLA Dr. Alan Brown welcomes Dr. Harold Bays, President of the Southeast Lipid Association and President of the Louisville Metabolic and Atherosclerotic Research Center in Louisville, KY. Dr. Bays led a novel educational effort to provide an annual summary of clinical lipidology to r…

1
Recognition and Management of Mental Illness for the Non-Psychiatric Clinician

8+ y ago

—

Host: Patrice L Basanta-Henry, MD, MHSc, FACOG Host Dr. Patrice Basanta Henry welcomes Dr Nzinga Harrison, Addiction Medicine & Psychiatrist, Campaign Psychiatrist for Let's Get Mentally Fit!, and, the CMO of ANKA Behavioral Health Incorporated. Dr. Harrison will discuss the importance of non-pyschiatric clinicians in recoginizing mentail illne…

1
The Life and Times of LDL Cholesterol

8+ y ago

—

Host: Harold Bays, MD, FNLA Dr. Harold Bays welcomes Dr, Alan Remaley, clinical pathologist and Section Chief of the Lipoprotein Metabolism Section in the Cardiopulmonary Branch of the National Heart Lung, and Blood Institute in Bethesda, MD. Their discussion centers on LDL cholesterol from a variety of little-known aspects: its history as a biomar…

1
Clinical Decisions on Cardiovascular Disease: Are Risks or Causes Your Guide?

8+ y ago

—

Host: Alan S. Brown, MD, FACC, FAHA, FNLA Guest: Allan Sniderman, MD Risk is calculated by a variety of algorithms, all of which produce an estimate for that individual based on age, gender, cholesterol, blood pressure, and smoking history. The estimate is critical to clinical decision-making, but how accurate is it? Host Dr. Alan Brown welcomes Dr…

1
Pathways Toward Better Lipid Medication Adherence

8+ y ago

—

Host: Alan S. Brown, MD, FACC, FAHA, FNLA Medication Adherence: is it the Achilles Heel in your therapies for patients with dyslipidemia? Dr. Lynne Braun, nurse practitioner in the Preventive Cardiology Center and the Heart Center for Women, and Professor in the Department of Adult Health Nursing at the Rush College of Nursing in Chicago, targets t…

1
Special Populations in Patient-Centered Management of Dyslipidemia

8+ y ago

—

Host: Alan S. Brown, MD, FACC, FAHA, FNLA Dr. Alan Brown welcomes Dr. Peter Jones, Associate Professor of Medicine and Atherosclorosis/Lipidology at Baylor College of Medicine in Houston, TX. They review special populations in the treatment of dyslipidemia, including Asians, women, elderly patients, and the immune-compromised. Supported by an Educa…

1
Updated NLA Recommendations for African American Patients

8+ y ago

—

Host: Alan S. Brown, MD, FACC, FAHA, FNLA Guest: Keith C. Ferdinand, MD, FACC, FAHA, FASPC, FNLA Host Dr. Alan Brown is joined by Dr. Keith C. Ferdinand, Professor at Tulane University School of Medicine in New Orleans, Louisiana. Dr. Ferdinand reviews the etiologies, diagnostic challenges, and management considerations for selective cardiac health…

1
Dyslipidemia in The Elderly: How Old is "Too Old" to Treat?

8+ y ago

—

Host: Alan S. Brown, MD, FACC, FAHA, FNLA Guest: Joyce Ross, MSN, CRNP, CS, CLS, FNLA, FPCNA One of the most recurrent questions that cardiologists and lipidologists face in daily practice is how to best approach the elderly patient with dyslipidemia. Joining Dr. Alan Brown for special considerations in this population and guideline-based recommend…

1
Dyslipidemia in Children and Adolescents

9y ago

—

Host: Alan S. Brown, MD, FACC, FAHA, FNLA Host Dr. Alan Brown welcomes Dr. Don Wilson, Endocrinologist at Cook Children's Health Care System, Fort Worth, Texas. Dr. Wilson will review dyslipidemia in children and adolescent patients. Key points of their discussion will cover the association between abnormal lipid levels in children and an increased…

1
Guidelines for Diagnosis and Management of Dyslipidemia in Patients with HIV

9y ago

—

Host: Alan S. Brown, MD, FACC, FAHA, FNLA In this session of Lipid Luminations, host Dr. Alan Brown welcomes Dr. Merle Myerson, founder and director of the Cardiovascular Disease Prevention Program, Lipid Clinic, Pre-Exercise Heart Screening Program, and Cardiology Section/Institute for Advanced Medicine (HIV) at Mount Sinai St. Luke's and Mount Si…

1
Million Hearts Initiative with Dr. Janet Wright, Executive Director

9y ago

—

Host: Alan S. Brown, MD, FACC, FAHA, FNLA Guest: Janet Wright, MD Heart disease and stroke are two of the leading causes of death in the United States. The Department of Health and Human Services, with several key partners, launched the Million Hearts national public-private initiative. Million Hearts aims to prevent one million heart attacks and s…

1
Dyslipidemia During Pregnancy: The Risks for Two Patients

9+ y ago

—

Host: Alan S. Brown, MD, FACC, FAHA, FNLA An old clinical dogma in OB/GYN was that dyslipidemia during pregnancy wouldn't have any long term implications on the developing fetus because of short exposures at 9 months. This has since been shown to be untrue. What health issues surface in children whose mothers experienced abnormally elevated lipid l…

1
Statin Intolerance: Keys to Patient Counseling and Guidance

9+ y ago

—

Host: Alan S. Brown, MD, FACC, FAHA, FNLA As many as 25% of patients taking statins may experience side effects. How should clinicians respond to the broad spectrum of side effects and variable severities reported? Host Dr. Alan Brown welcomes Dr. John Guyton, Associate Professor of Medicine and Assistant Professor of Pathology at Duke University S…

1
Roles of Non-HDL Cholesterol in Risk Assessment and Treatment

9+ y ago

—

Host: Alan S. Brown, MD, FACC, FAHA, FNLA A paradigm shift in the management of lipid disorders has been witnessed of late based on evidence reviews by the AHA and the ACC. Where the clinical dogma once focused on targeting specific lipoproteins, clinicians are now trending toward using appropriate dosages of statins for lowering non-HDL cholestero…

1
Keys to the Latest NLA Recommendations for Dyslipidemia Treatments

9+ y ago

—

Host: Alan S. Brown, MD, FACC, FAHA, FNLA What's the evidence for LDL and other non-HDL targets for primary and secondary prevention of heart disease? What are the comparative benefits versus toxicities of all lipid-lowering medications in clinical use? Addressing these and other questions from the standpoing of recent NLA recommendations is Kevin …

1
Management of the Patient With Triglycerides 200-499 mg/dl.

9+ y ago

—

Host: Alan S. Brown, MD, FACC, FAHA, FNLA Guest: Carl Orringer, MD, FACC, FNLA What are some of the causes of high triglycerides? What is the biggest health risk? And, for these patients, at what level is the risk greater for developing pancreatitis and coronary artery disease? Host Dr. Alan Brown welcomes Dr. Carl Orringer, Associate Professor of …

1
What is the Safety of Statins in Patients with Diabetes?

10y ago

—

Guest: Kevin C. Maki, PhD, FNLA, CLS Host: Alan S. Brown, MD, FACC, FAHA, FNLA At the most recent National Lipid Association (NLA) meeting, host Dr. Alan Brown welcomes Kevin Maki, PhD, FNLA, CLS, Chief Science Officer for Midwest Center for Metabolic and Cardiovascular Research and Adjunct Faculty position in Biostatistics and Applied Epidemiology…

1
A Synopsis of the ACC/AHA Risk Assessment and Cholesterol Guidelines

10y ago

—

Guest: Anne Goldberg, MD Host: Alan S. Brown, MD, FACC, FAHA, FNLA Host Dr. Alan Brown is joined by Anne Goldberg, MD, Associate Professor of Medicine at Washington University School of Medicine and a member of the ACC/AHA Blood Cholesterol Guidelines Panel. Dr. Goldberg will provide a review of the panel assembled by National Heart, Lung, and Bloo…

1
National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia

10y ago

—

Guest: Kevin C. Maki, PhD, FNLA, CLS Guest: Carl Orringer, MD, FACC, FNLA Guest: Harold Bays, MD, FNLA Host: Alan S. Brown, MD, FACC, FAHA, FNLA Guest: Matthew Ito, PharmD, FNLA Host Dr. Alan Brown is joined by an expert panel to discuss the NLA's latest draft document that will serve as recommendations to clinicians for the management of patients …

1
New Insights on Statin Therapy for Older Patients

10+ y ago

—

Host: Alan S. Brown, MD, FACC, FAHA, FNLA Is there a patient age at which statin therapy should be discontinued? Likewise, what does the current evidence tell us about initiating vs not initiating statin therapy in older patients? Joining Lipid Luminations to discuss these and other important questions is Dr. W. Virgil Brown, Charles Howard Candler…

1
HPS-2 THRIVE Data and Results

10+ y ago

—

Host: Alan S. Brown, MD, FACC, FAHA, FNLA Joining host Dr. Alan Brown is Dr. John Guyton, Associate Professor of Medicine and Assistant Professor of Pathology of the Division of Medicine-Endocrinology and Metabolism at Duke University School of Medicine. Their discussion will focus on data and results from HPS-2 THRIVE, a large-scale stud…

1
Health Information Technology's Impact on Adherence to Lipid Therapy

10+ y ago

—

Host: Alan S. Brown, MD, FACC, FAHA, FNLA Health information technologies have evolved dramatically from simplistic documentation devices early on to sophisticated drivers of quality patient care today. This emergence is having a particularly positive effect on treatment for dyslipidemia. Joining host Dr. Alan Brown to reflect on a recent NLA manus…

Podcasts Worth a Listen

Pcsk9 Podcasts

Podcasts Worth a Listen

Quick Reference Guide